Related Experiment Video
Updated: Jul 8, 2026
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Characterization of the CXCR4 signaling in pancreatic cancer cells
Daniel D Billadeau1, Subrha Chatterjee, Patricia Bramati
1Oncology Research Department, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Abstract:
CXCL12 and its receptor, CXCR4, are emerging as promising targets for modulating growth, angiogenesis, and metastasis in several human cancers. Indeed, blocking the receptor is sufficient to prevent metastasis and angiogenesis in experimental breast cancer xenografts. Recently, the biological effect of the CXCR4 in pancreatic cancer, one of the most deadly neoplastic diseases, has been reported. However, the molecular mechanism by which CXCR4 contributes to these properties is not completely understood. In this paper, we characterize the signaling pathways activated by CXCR4 in pancreatic cancer. We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Analysis of this cascade in pancreatic cancer cells revealed that the ERK-mediated pathway regulates genes involved in angiogenesis, such as VEGF, CD44, HIF1alpha, and IL-8. Furthermore, ERK blockage inhibits the migration and tube formation of endothelial cells induced by CXCL12. Considering that inhibitors for several components of this pathway, including CXCR4 itself, are at different stages of clinical trials, this study provides theoretical justification for the clinical testing of these drugs in pancreatic cancer, thus extending the list of potential targets for treating this dismal disease.
Insights
CXCR4 signaling in pancreatic cancer activates ERK, promoting angiogenesis and metastasis. Inhibiting this pathway offers a new therapeutic strategy for this deadly disease.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- CXCL12/CXCR4 axis is crucial for cancer growth, angiogenesis, and metastasis.
- CXCR4 plays a role in pancreatic cancer, but its molecular mechanisms remain unclear.
- Pancreatic cancer is a highly lethal neoplastic disease with limited treatment options.
Purpose of the Study:
- To elucidate the signaling pathways activated by CXCR4 in pancreatic cancer.
- To identify key molecular players in CXCR4-mediated oncogenic processes.
- To provide a rationale for targeting the CXCR4 pathway in pancreatic cancer therapy.
Main Methods:
- Investigated CXCR4 signaling in pancreatic cancer cells.
- Analyzed receptor tyrosine phosphorylation (EGFR) and kinase activities (MMPs, Src, PI3-Kinase).
- Assessed ERK pathway activation and its downstream gene targets (VEGF, CD44, HIF1alpha, IL-8).
- Evaluated the effect of ERK inhibition on endothelial cell functions.
Main Results:
- CXCR4 activation leads to EGFR phosphorylation and subsequent activation of MMPs, Src, and PI3-Kinase.
- These kinases are essential for CXCR4-mediated ERK activation.
- ERK signaling regulates angiogenesis-related genes (VEGF, CD44, HIF1alpha, IL-8) in pancreatic cancer.
- Inhibition of ERK blocks CXCL12-induced endothelial cell migration and tube formation.
Conclusions:
- The CXCR4/EGFR/ERK signaling cascade is a key mechanism driving angiogenesis and metastasis in pancreatic cancer.
- Targeting components of this pathway, including CXCR4 and ERK, holds therapeutic potential.
- This study supports clinical trials of CXCR4 pathway inhibitors for pancreatic cancer treatment.
